DRREDDY · Dr. Reddy S Laboratories · Biotechnology & Drugs
As of 05 Nov close
52-week range
3.5% below 52-week high
52-week range: as of 05 Nov 2026 close.
Slowest input: promoter pledge (disclosed quarterly), as of 18 Jul 2026
Stock Condition
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Stock Condition as of 05 Nov 2026 close
What the data shows
- Trend (10d)
- Sector standing
- Delivery (previous session)
- FII flow (5d)
- PCR
- RSI (14)
- Promoter pledge
- Insider activity (30d)
- Volume vs usual (5-day vs 20-day)
- 0.76x its usual level
- Growth trend
- Revenue grew -5.51% YoY last quarter (no multi-quarter acceleration streak on file).
- Valuation vs peers
- Trailing P/E of 35.07 sits inline the sector average of 36.32.
- Event risk (5d)
Data as of 05 Nov 2026
Data as of 05 Nov 2026
Data as of 04 Nov 2026
Data timestamp unavailable
Data as of 05 Nov 2026
Data as of 05 Nov 2026
Data as of 18 Jul 2026
Data timestamp unavailable
Data as of 05 Nov 2026
Data timestamp unavailable
Data timestamp unavailable
Data timestamp unavailable
Signal changes and why the Stock Condition changed
Why did this change?
DRREDDY's Stock Condition eased from 70 to 67 on 5 Nov (-3).
- ▲Price trend: Trend reading improved vs yesterday
- –Volume participation: volume held near its recent norm
- ▼Delivery participation: delivery participation weakened
- –Momentum (RSI): RSI held steady
- ▼Sector standing: industry standing weakened
- –Options positioning (PCR): options positioning held steady
- –Promoter pledge: promoter pledge unchanged
- –Insider activity: insider filings unchanged
- –FII flow context: FII flow backdrop unchanged
▲ improved · ▼ weakened · – unchanged
The data shows the change but not its cause — several explanations are usually possible.
Signal Change Log
- 05 Nov-3Stock Condition eased 3 points on shifts across underlying measured values
- 04 Nov-7Stock Condition eased 7 points on shifts across underlying measured values
- 03 Nov+3FII flows ran net-positive
- 03 Nov+3sector state cleared (sector strong no longer applied)
- 02 Nov-8volume state cleared (volume elevated no longer applied)
- 29 Oct+10sector moved into the top ranks
- 28 Oct+8delivery state cleared (delivery down no longer applied)
- 27 Oct-2delivery signal weakened
- 27 Oct-2volume ran above its recent norm
- 27 Oct-2sector state cleared (sector strong no longer applied)
- 26 Oct+14RSI entered its upper zone
- 26 Oct+14sector moved into the top ranks
- 26 Oct+14options state cleared (pcr call heavy no longer applied)
- 23 Oct+110-day trend turned positive
- 22 Oct+4options positioning turned call-heavy
- 22 Oct+4trend state cleared (trend up 10d no longer applied)
- 22 Oct+4volume state cleared (volume muted no longer applied)
- 22 Oct+4fii state cleared (fii sell streak no longer applied)
- 21 Oct-110-day trend turned positive
- 21 Oct-1volume fell below its recent norm
- 19 Oct+3Stock Condition rose 3 points on shifts across underlying measured values
- 16 Oct+2options state cleared (pcr call heavy no longer applied)
- 15 Oct+3price held above its 20-day average
- 15 Oct+3options positioning turned call-heavy
- 15 Oct+3trend state cleared (trend down 10d no longer applied)
- 14 Oct-710-day trend turned negative
- 13 Oct-6Stock Condition eased 6 points on shifts across underlying measured values
- 12 Oct+6options state cleared (pcr call heavy no longer applied)
- 09 Oct+7Stock Condition rose 7 points on shifts across underlying measured values
- 08 Oct-9options positioning turned call-heavy
- 08 Oct-9trend state cleared (above 20dma no longer applied)
- 08 Oct-9volume state cleared (volume elevated no longer applied)
- 07 Oct-10Stock Condition eased 10 points on shifts across underlying measured values
- 06 Oct-3Stock Condition eased 3 points on shifts across underlying measured values
Related news
- lowthehindubusinessline.com· 26 Oct 2026, 12:36 pmDr. Reddy’s shares rise 5% despite cautious analyst outlook
- lowseekingalpha.com· 24 Oct 2026, 04:37 amDr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript
- loweconomictimes.indiatimes.com· 19 Oct 2026, 05:59 amPharma Q2 Outlook: Pricing pressure, US competition to weigh on select players
- lowlivemint.com· 14 Oct 2026, 01:15 pmMutual funds' September 2026 portfolio moves: Top 5 stocks bought and sold across large-, mid- and small-cap segments
- lowzacks.com· 13 Oct 2026, 12:54 amTop Stock Reports for Oracle, American Express & Progressive
- mediummacrothehindubusinessline.com· 07 Oct 2026, 09:51 amNifty falls on RBI rate decision day; Titan, SBI Life lead declines